We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+4.22%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$7.22B
AUM Growth
+$986M
Cap. Flow
+$1.27B
Cap. Flow %
17.6%
Top 10 Hldgs %
44.55%
Holding
109
New
17
Increased
12
Reduced
6
Closed
14

Top Buys

Rank Stock Value
1
CLYM
Climb Bio
CLYM
+$272M
2
CTKB icon
Cytek Biosciences
CTKB
+$226M
3
IVVD icon
Invivyd
IVVD
+$198M
4
ICVX
Icosavax, Inc. Common Stock
ICVX
+$196M
5
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$177M

Top Sells

Rank Stock Value
1
AXSM icon
Axsome Therapeutics
AXSM
+$112M
2
NVAX icon
Novavax
NVAX
+$102M
3
CRIS icon
Curis
CRIS
+$57.6M
4
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$56.4M
5
TRIL
Trillium Therapeutics Inc.
TRIL
+$51.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.06%
2 Financials 0.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRDS
76
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$9.95M 0.14%
1,000,000
– –
CNCE
77
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$9.92M 0.14%
3,033,603
– –
ARYE
78
DELISTED
ARYA Sciences Acquisition Corp V Class A Ordinary Shares
ARYE
$9.88M 0.14%
+1,000,000
New +$9.93M
FLACU
79
DELISTED
Frazier Lifesciences Acquisition Corporation Unit
FLACU
$9.82M 0.14%
1,000,000
– –
IMA
80
ImageneBio Inc
IMA
$64.9M
$9.46M 0.13%
62,500
– –
PHAS
81
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$8.86M 0.12%
2,850,000
– –
HLTH
82
DELISTED
Cue Health Inc. Common Stock
HLTH
$8.86M 0.12%
+750,000
New +$11.8M
COGT icon
83
Cogent Biosciences
COGT
$7.32B
$8.63M 0.12%
1,025,641
– –
CGEM icon
84
Cullinan Oncology
CGEM
$1.08B
$7.9M 0.11%
350,000
– –
OCUL icon
85
Ocular Therapeutix
OCUL
$1.89B
$7.5M 0.1%
750,000
– –
FVAM
86
DELISTED
5:01 Acquisition Corp
FVAM
$7.37M 0.1%
750,000
– –
MLTX icon
87
MoonLake Immunotherapeutics
MLTX
$1.53B
$6.96M 0.1%
700,000
– –
OBIO icon
88
Orchestra BioMed
OBIO
$256M
$6.18M 0.09%
625,000
– –
BMEA icon
89
Biomea Fusion
BMEA
$88.9M
$5.99M 0.08%
500,000
– –
CVRX icon
90
CVRx
CVRX
$146M
$4.55M 0.06%
275,000
– –
SYRS
91
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$4.02M 0.06%
90,000
– –
CCXI
92
DELISTED
ChemoCentryx, Inc.
CCXI
$3.74M 0.05%
218,532
-3,278,107
-94% -$51.1M
OTIC
93
DELISTED
Otonomy, Inc.
OTIC
$3.13M 0.04%
+1,631,635
New +$2.77M
OKUR
94
OnKure Therapeutics
OKUR
$166M
$464K 0.01%
6,222
– –
VRDN icon
95
Viridian Therapeutics
VRDN
$2.3B
$17K ﹤0.01%
1,034
-311,294
-100% -$4.57M
ARDX icon
96
Ardelyx
ARDX
$1.24B
– –
-6,077,294
Closed -$46.1M
AXSM icon
97
Axsome Therapeutics
AXSM
$10.9B
– –
-1,655,447
Closed -$112M
CRIS icon
98
Curis
CRIS
$9.2M
– –
-17,850
Closed -$57.6M
ELVN icon
99
Enliven Therapeutics
ELVN
$4.37B
– –
-62,201
Closed -$1.97M
INZY
100
DELISTED
Inozyme Pharma
INZY
– –
-2,003,653
Closed -$34.1M
1 2 3
4
5

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, RA Capital Management held 109 positions worth $7.22B, up 16% from $6.23B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

RA Capital Management deployed $1.27B of net new capital in Q3 2021, opening 17 new positions and adding to 12 existing holdings. Its largest new stake was Climb Bio: 13,150,849 shares worth $236M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Novavax, an estimated $102M trimmed.

  • RA Capital Management's largest Q3 2021 buy was Climb Bio: 13,150,849 shares worth $236M.
  • RA Capital Management added most to Ascendis Pharma A/S in Q3 2021, an estimated $79.6M increase.
  • RA Capital Management's biggest Q3 2021 reduction was Novavax, cutting an estimated $102M.
  • RA Capital Management fully exited Axsome Therapeutics in Q3 2021, selling an estimated $112M.
  • RA Capital Management's ten largest holdings make up 45% of its $7.22B portfolio in Q3 2021.
  • RA Capital Management opened 17 new positions and closed 14 in Q3 2021.
  • RA Capital Management's portfolio value rose 16% quarter-over-quarter to $7.22B.

Based on RA Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.